Iterum Therapeutics PLC
NASDAQ:ITRM
EV/IC
Enterprise Value to IC
Enterprise Value to Invested Capital (EV/IC) ratio is a valuation multiple that measures the dollars in Enterprise Value for each dollar of capital invested by shareholders and lenders.
Market Cap | EV/IC | ||||
---|---|---|---|---|---|
IE |
Iterum Therapeutics PLC
NASDAQ:ITRM
|
25.5m USD | -7.7 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 032 690.2 | |
US |
Eli Lilly and Co
NYSE:LLY
|
717.4B USD | 12.6 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 14.7 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 326.4 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
362.1B USD | 2.7 | ||
US |
Merck & Co Inc
NYSE:MRK
|
325.6B USD | 3.6 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
190.9B GBP | 32.2 | ||
CH |
Novartis AG
SIX:NOVN
|
182.1B CHF | 2.6 | ||
CH |
Roche Holding AG
SIX:ROG
|
181.6B CHF | 2.6 | ||
US |
Pfizer Inc
NYSE:PFE
|
160B USD | 1 |
EV/IC Forward Multiples
Forward EV/IC multiple is a version of the EV/IC ratio that uses forecasted invested capital for the EV/IC calculation. 1-Year, 2-Years, and 3-Years forwards use invested capital forecasts for 1, 2, and 3 years ahead, respectively.